Cctv news: On June 15th, 2018, National Medical Products Administration officially approved the listing of PD-1 antibody Nivolumab injection in China. The indications are: patients with advanced non-small cell lung cancer who failed standard chemotherapy. Experts pointed out that the listing of this new drug will bring new treatment methods and hope for patients with advanced non-small cell lung cancer.
The highest incidence of lung cancer is 85% non-small cell.
Lung cancer is the leading cause of cancer death in the world. According to the statistics of the World Health Organization, more than 1.7 million people die of lung cancer every year. Lung cancer is the most common cancer in China, among which non-small cell lung cancer is the most common type, accounting for about 85% of all lung cancer patients.
Yang Zhimin, Director of Clinical Department I of Chemical Medicine of National Medical Products Administration Drug Evaluation Center.
Yang Zhimin, Director of Clinical Department I of Chemical Medicine of National Medical Products Administration Drug Evaluation Center.Compared with traditional chemotherapy and small molecule targeted therapy, it is completely different from the mechanism of action. Studies in China have also proved that the use risk of it for these advanced non-small cell (lung cancer) patients can be significantly reduced by 32%.
Long-term survival of patients with advanced malignant melanoma
In July 2014, the world’s first PD-1 inhibitor was launched in Japan for the treatment of advanced malignant melanoma. Clinical studies have found that some patients who have been relieved after treatment have achieved long-term survival, so PD-1 inhibitors have attracted wide attention all over the world. Since then, the United States, the European Union, Australia, Hong Kong and other places have completed the listing of PD-1 inhibitors.
Breaking the tradition and bringing about breakthrough progress across multiple cancers
In 2016, the American Science magazine selected this cancer immunotherapy as the biggest scientific breakthrough of the year. Because it not only completely broke the traditional cancer treatment; Moreover, it has also brought about breakthrough progress across multiple cancer species, and some advanced patients have achieved long-term survival.
National Medical Products Administration said that at present, similar domestic new drugs are also being developed, and some have entered the review stage.
Yang Zhimin, Director of Clinical Department I of Chemical Medicine of National Medical Products Administration Drug Evaluation Center.From the current point of view, we hope that the priority review time can be shortened to four to six months as far as possible in the future, and the listing will be approved.